Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
47 hedge funds and large institutions have $17.9M invested in Clearside Biomedical in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 9 closing their positions.
0.16% less ownership
Funds ownership: 1.39% → 1.23% (-0.16%)
8% less funds holding
Funds holding: 51 → 47 (-4)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
25% less capital invested
Capital invested by funds: $23.8M → $17.9M (-$5.86M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$450K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$365K |
| 3 |
BlackRock
New York
|
+$51.4K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$47.7K |
| 5 |
Renaissance Technologies
New York
|
+$46.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.34M |
| 2 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
-$260K |
| 3 |
CP
Castleview Partners
Dallas,
Texas
|
-$248K |
| 4 |
Millennium Management
New York
|
-$211K |
| 5 |
Jane Street
New York
|
-$191K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CP
51
Castleview Partners
Dallas,
Texas
| – | -$248K | -10,797 | Closed |
|
|
YIH
52
Y-Intercept (HK)
Hong Kong
| – | -$52.2K | -2,275 | Closed |
|
53
SG Americas Securities
New York
| – | -$49K | -2,151 | Closed |
|
54
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$38.9K | -1,694 | Closed |
|
|
CSS
55
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$37.6K | -1,638 | Closed |
|
56
UBS Group
Zurich,
Switzerland
| – | -$11.7K | -512 | Closed |
|
|
HGERS
57
Householder Group Estate & Retirement Specialist
Scottsdale,
Arizona
| – | -$589 | -26 | Closed |
|
CLSD Hedge Fund Activity: Q2 2024 in Review
47 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2024, worth a combined $17.9M — down 25% from $23.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CLSD and 6 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $450K. The largest seller was Armistice Capital, cutting an estimated $2.34M.
- 47 institutional investors held Clearside Biomedical (CLSD) as of Q2 2024, down from 51 in Q1 2024.
- Funds reported $17.9M of Clearside Biomedical stock for Q2 2024, down 25% quarter-over-quarter.
- 6 funds opened new Clearside Biomedical positions in Q2 2024 and 9 closed out, a net change of -3 holders.
- The largest Clearside Biomedical buyer in Q2 2024 was Vanguard Group, an estimated $450K added.
- The largest Clearside Biomedical seller in Q2 2024 was Armistice Capital, an estimated $2.34M sold.
Based on aggregated 13F filings for Q2 2024.